Extended Data Fig. 4: Proportion of type 2 diabetes drug targets with human genetic support by highest phase reached.
From: Refining the impact of genetic evidence on clinical success
A) OMIM, B) established (2019 and earlier) GWAS genes, C) novel (new in Vujkovic 2020 or Suzuki 2023) GWAS genes, or D) any of the above. See Methods for details on GWAS dataset processing. N is indicated at right of each panel, with denominator being the number of T2D targets at each stage and the numerator being the number of those that are genetically supported. Total N = 284 targets. The center is the exact proportion and error bars are Wilson binomial 95% confidence intervals.